Palladio Biosciences, Inc., is a Centessa company. Their first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys.  It is a life-limiting, chronic and progressive disease.

Biotechnology

Palladio Biosciences

Palladio Biosciences' headquarters in Horsham, PA, United States

Alex Martin

Ron Dadino

Description

People

Jobs